Invest2 publishers2 min readPublished
Existing shareholders were selling most of the stock in Oura's postponed $2.2 billion IPO
Oura postponed a $2.2 billion Nasdaq IPO in which existing holders were selling 36.5 million of the 50 million shares, a week after launching it. With at most $594 million going to the company, the delay fits sellers turning down a lower price as well as it fits a closed window.
The Investor · Invest desk
What happened
- Oura blamed uncertainty in the IPO market, while saying demand was strong and the business had strengthened since the process began.
- The company says it is profitable, expects revenue to grow 90% in fiscal 2026 and has 5.7 million paid members.
- Eli Lilly had signaled it might buy up to $100 million of shares and Dragoneer up to $300 million, according to Reuters.
Compiled by The InvestorSomething wrong?How this is made
Why it matters
- cost The wait falls mostly on existing stockholders, who supplied about 73% of the base offering and now have no exit, while Oura defers only the smaller slice of new cash.
- contradiction Oura calls demand strong yet walked away; the two claims square only if the strong demand sat below the range its selling shareholders wanted.
- exposure Last October's $11 billion Series E sits about 30% under the IPO valuation, so a relaunch can come in cheaper for a long way before it undercuts the latest private round.
Oura's own 13.5 million shares [9], sold at $40 to $44 [2], would have raised $540 million to $594 million [1]. The 36.5 million offered by existing stockholders [9] would have raised $1.46 billion to $1.61 billion [2]. None of that money would have reached the company [11]. The sellers also planned to give the underwriters a 30-day option on 7.5 million more shares [10], worth up to $330 million at $44 [4].
Those proportions decide who pays for the delay. Oura's revenue was $1.21 billion for the nine months to June 30 [13], roughly $1.61 billion a year at that pace [5], and it has raised more than $1.5 billion privately, including a $900 million Series E last October at an $11 billion valuation [14]. A company that reports a profit [6] and has that funding behind it can go without $594 million for a while. Tom Hale, the chief executive, said: "We aim to deliver an extraordinary IPO for our employees and investors and we have the luxury of choosing our moment." [4] He added: "In the meantime, we will execute against the opportunities ahead." [5]
If the window is simply shut, Oura is one casualty among several. Holtec Nuclear pulled its IPO this month [8], and Reuters describes investors rattled by the Federal Reserve's rate hike, geopolitical turmoil and swings in AI stocks [7]. A price problem would mean buyers offered less than $40 [2] and the sellers said no. Hale's own account allows a third version, in which the book was covered at the range and the company chose to wait. The company did not disclose the order book. The indications Reuters reported from Eli Lilly and Dragoneer add up to $400 million, about 18% of the $2.2 billion on offer [9].
I think price fits the evidence best. The range valued Oura 42% above the Series E [7] and at about 9.7 times its annualized nine-month revenue [6], and most of the stock was coming from holders who would have sold at that level [9]. The counter-case is real: a second withdrawal in the same month [8] suggests the whole calendar is stuck, and a stuck calendar says nothing about any one company's quality. The market sets the price an issuer is offered, and a company that reports a profit and needs little of the cash can turn that price down [6]. The view is wrong if Oura comes back at $40 or more with the same mix of new and existing shares [9]. A lower range, or fewer shares from existing holders, would bear it out.
What to watch
- Whether another profitable issuer prices at or above its range this fall; a clean pricing would weaken the reading that the window is shut for everyone.
- Whether the Eli Lilly and Dragoneer indications carry over to a relaunched Oura deal.
- Oura's fiscal 2026 results against the 90% revenue growth it forecast while marketing the deal.